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Finally, it is obvious that together we agree that color M-mode
Doppler is a new and interesting noninvasive method for the evalua-
tion of diastolic function.
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Is Pharmacologic Cardioversion of Atrial
Fibrillation Really Preferable to
Electrical Cardioversion?
Harjai et al. (1), in a nonrandomized study, conclude that patients
undergoing electrical cardioversion of atrial fibrillation (AF) display a
“greater degree and longer duration” of mechanical atrial dysfunction
than those who convert pharmacologically or spontaneously. The authors
strongly imply that this finding is a result of the mode of cardioversion.
However, examination of their data reveals that this conclusion is unsup-
ported and, indeed, that an absence of effect is more likely.
There are several flaws in the authors’ analyses and logic. We
would first question whether it is valid, in such a small study of
cardioversion of atrial fibrillation, to include patients who spontane-
ously revert to sinus rhythm. Spontaneous conversions often occur in
the first week of the arrhythmia (2). In a group with a median duration
in excess of 1 month, inclusion of spontaneous convertors with pharma-
cologic converters may bias the data in favor of the latter because, as the
authors point out, a duration of AF ,7 to 14 days has been previously
shown to be associated with better postconversion atrial recovery. Indeed,
reference to Table 1 indicates that almost twice as many patients in the
nonelectrical converter group had an arrhythmia duration ,28 days—a
difference that fails to reach statistical significance only on the basis of the
very small numbers in the former group.
The arbitrary division of AF duration into those with a duration
,28 or .28 days is also problematic. Because previous studies have
demonstrated that an AF duration ,14 days is associated with less
depression of postreversion A wave height (3), the authors should have
analyzed the effects of a shorter arrhythmia duration on A wave
recovery. Indeed, the use of AF duration as a continuous, rather than
a dichotomous, variable would have better elucidated the role of
duration of AF on atrial function.
Multivariate analysis is generally accepted as the “gold” standard in
determining whether a variable is truly associated with an outcome.
When adjusted for several other clinical variables (AF duration, left
atrial size and ejection fraction), the authors state that the mode of
cardioversion was not associated with recovery of atrial electrome-
chanical function, yet they seem to ignore this finding and conclude
from “bivariate analysis” that “only the mode of cardioversion was
seen to have any impact on the recovery of atrial function.”
Finally, it is in our opinion, inaccurate to categorize this study as a
comparison between patients undergoing either pharmacologic or
electrical cardioversion. Presumably, many of the patients who subse-
quently underwent electrical cardioversion had been prescribed an
antiarrhythmic agent either in an attempt to convert the arrhythmia or
to maintain sinus rhythm after cardioversion. If this is so, then the
study is predominantly a comparison of patients who responded to
pharmacologic agents with those in whom pharmacologic conversion
failed. Seen in this light, attributing postreversion atrial stunning to the
mode of reversion is inaccurate.
Whether pharmacologic cardioversion of AF produces less atrial
mechanical dysfunction than electrical cardioversion is an interesting
question that may have some bearing on postconversion risk of
thrombus formation. However, the answer to this question will require
a randomized trial of immediate, drug-free electrical conversion
compared with pharmacologic conversion. Failure to convert, either
electrically or pharmacologically, will have to be treated as failure to
recover mechanical atrial function. To retain a high likelihood of
pharmacologic conversion, entry should probably be limited to those
patients with a short (,7 or ,14 days) arrhythmia duration. Only the
results of such a study can give meaningful answers to the question of
whether the atrium really cares how sinus rhythm is restored (4).
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Reply
We agree with Falk and colleagues that a randomized trial of electrical
versus pharmacologic cardioversion would be the best way to assess the
impact of mode of cardioversion on postcardioversion atrial mechan-
ical dysfunction. Although our study (1) was not a randomized trial, it
represents the only attempt so far to address this issue after multivar-
iate adjustment for other clinical variables that could potentially
influence postcardioversion atrial function. Of all the variables tested,
only the mode of cardioversion was seen to have any influence on the
recovery of atrial function. It is noteworthy that the delay in mechan-
ical recovery of atrial function that was associated with electrical (vs.
nonelectrical) cardioversion was significant after adjustment for pa-
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tient age, underlying cardiovascular disease or use of antiarrhythmic
drug therapy, but not so after adjustment for left ventricular ejection
fraction, left atrial diameter or duration of atrial fibrillation. We feel
that our results justify the conclusion that “patients who undergo
electrical cardioversion display a greater degree and longer duration of
mechanical atrial dysfunction than those who convert pharmacologi-
cally or spontaneously” (1).
We agree with Falk et al. that some of the patients who underwent
electrical cardioversion may have had attempts at pharmacologic
cardioversion in the past. By the same token, some of the patients who
had pharmacologic cardioversion in our study had also undergone
previous attempts at cardioversion. Previous history of cardioversion
attempts was not specifically monitored in our study; hence, we are
unable to comment on the actual number of study patients who had
had previous attempts at cardioversion. To say that “the study is
predominantly a comparison of patients who responded to pharmaco-
logic agents compared with those in whom pharmacologic cardiover-
sion failed” is therefore erroneous.
To the best of our knowledge, there is only one previous study that
showed that duration of atrial fibrillation ,14 days (vs. .6 weeks) is
associated with faster recovery of atrial function (2). In that particular
study, no multivariate analysis was performed to account for differ-
ences between groups of patients who had atrial fibrillation ,14 days
versus .6 weeks. For this reason, we are not convinced that atrial
fibrillation duration ,14 days should be a standard reference division
point for all future studies with regard to atrial fibrillation. Until more
definitive information is available on the impact of duration of atrial
fibrillation on atrial function recovery, any dichotomization of this
variable will have to be “arbitrary.” The division of atrial fibrillation
duration in our study is identical to the inclusion criterion used by Falk
et al. in their study addressing postcardioversion atrial function (3).
Due to uncertainty about the exact duration of atrial fibrillation in
many cases, it is not feasible to use duration of atrial fibrillation as a
continuous variable.
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Before Predicting Survival in Children With
Pulmonary Hypertension and Congenital
Heart Disease . . .
In the recent article by Clabby et al. (1), the authors provide very
interesting data on the predictive value of hemodynamic data with
respect to survival in pediatric patients with primary and secondary
pulmonary hypertension. In primary pulmonary hypertension, such
data have been reported earlier (2,3). In patients with plexogenic
arteriopathy and congenital heart disease, these data are scarce (4).
The design of this study has led to the pitfalls of highly selected
patient population and small sample size in relation to the used
analysis techniques, and consequently the results have to be inter-
preted with great caution. The most serious problem with the study
design is the composition of group 2. This group includes patients with
repaired and unrepaired heart defects, which leads to two comments
on the interpretation of the data:
1. In patients with persistent pulmonary hypertension after ade-
quate surgical repair of a heart defect, hemodynamic variables are
comparable to those in patients with primary pulmonary hypertension.
In contrast, in patients with unrepaired heart defects or residual
shunts, hemodynamic variables cannot be interpreted in the same way.
The authors suggest that the variable “mean right atrial pressure
(mRAP) 3 pulmonary vascular resistance (PVR)” represents the
pressure load on the right ventricle and indicates how well the right
ventricle handles that pressure. However, in children with large
intracardiac communications, with or without transposition of the
great arteries, increased PVR is not simply a pressure load for the right
ventricle and ventricular dysfunction does not necessarily lead to
increased mRAP.
2. More important, the authors conclude that survival in children
with pulmonary hypertension in the presence of congenital heart
defects, as predicted by the suggested hemodynamic variables, can be
used to determine the optimal timing of lung transplantation. How-
ever, before predicting survival or scheduling lung transplantation, the
question to be addressed is whether the pulmonary arteriopathy has
progressed to the irreversible stage. Pulmonary plexogenic arteriopa-
thy in children with left to right shunts is a reversible disease until a
so-called “point of no return” is reached, at which the process has
become irreversible, and progression will occur even if the heart defect
is corrected (5). In the reversible stage, the treatment of choice will
obviously be surgical correction of the heart defect. It can be specu-
lated that the pulmonary vascular disease might have been still
reversible in some of the study patients: In 80% of group 2 patients, the
heart defect was unrepaired or palliated, or residual defects were
present, whereas right to left shunting was present in only 29%.
Hemodynamic or histologic evaluation is currently used to assess the
progression of pulmonary vascular disease. However, criteria to pre-
dict in which patients pulmonary vascular disease will progress despite
surgical correction have a broad gray zone (5,6). Therefore, before
including these children in a study to predict survival in patients with
irreversible pulmonary vascular disease, we should be able to deter-
mine the reversibility of this disease process more accurately.
In other words, one does not want to predict the optimal timing for
lung transplantation in children who may be cured by surgical correc-
tion of their heart disease.
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